AGMB vs AKTX

AgomAb Therapeutics NV vs Akari Therapeutics Plc — Valuation Comparison 2026

AGMB

Biotechnology
AgomAb Therapeutics NV
Quality
1.8
out of 10
Value Trap
Price
$11.54
Last close
Models
7/13
Active
VS

AKTX

Biotechnology
Akari Therapeutics Plc
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$22.05
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType AGMB Fair ValueAGMB Upside AKTX Fair ValueAKTX Upside
Bayesian DCF Intrinsic $3.06 -73.5% $5.78 -73.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $13.95 +20.9% $23.73 +307.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AGMB vs AKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AGMB vs AKTX — Which Stock Is More Undervalued?

AGMB scores higher with a 1.8/10 quality rating vs AKTX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AgomAb Therapeutics NV (AGMB) and Akari Therapeutics Plc (AKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AGMB currently trades at $11.54 with a QOC of 1.8/10, while AKTX trades at $22.05 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).